Table 3.
Clinical trials listed on clinicaltrials.gov for multiple sclerosis.
| No | Disease | Sponsor | Cell type | Route | Cell dose | Planned participants | Year | Phase | Clinical trial # |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MS | Tisch Multiple Sclerosis Research Center of New York | Autologous MSC-derived neural progenitors (MSC-NP) | IT | 6-30M | 20 | 2014 | 1 | NCT01933802 |
| 2 | MS | Tisch Multiple Sclerosis Research Center of New York | Autologous MSC-derived neural progenitors (MSC-NP) | IT | Not mentioned | 50 | 2018 | 2 | NCT03355365 |
| 3 | Progressive Multiple Sclerosis | IRCCS San Raffaele | Fetal-derived NSC | IT | 0.7 M, 1.4 M, 2.8 M, 5.7 M | 4 | 2017 | 1 | NCT03269071 |
| 4 | Secondary progressive MS | Casa Sollievo della Sofferenza IRCCS | Fetal-derived NSC | Intraventricular | 5, 10, 16, and 24 M | 24 | 2017 | 1 | NCT03282760 |
| 5 | Primary progressive MS | Joanne Kurtzberg | UCB-derived oligodendrocyte-like cells (DUOC-01) | IT | 10 M (3 pax), 10-25 M (3 pax), 25-50 M (16pax) | 20 | 2021 | 1a | NCT04943289 |
| 6 | MS | Baylor College of Medicine | Autologous CD34+ HSC | IV | 3 M | 10 | 1999 | 2 | NCT00040482 |
| 7 | MS | Ottawa Hospital Research Institute | Autologous CD34+ HSC | IV | Not mentioned | 24 | 2001 | 2 | NCT01099930 |
| 8 | MS | Hadassah Medical Organization | Autologous T cell | SubC | 10-30 M cells (×4 doses) | 30 | 2002 | 1/2 | NCT01448252 |
| 9 | Relapse Remitting MS/secondary Progressive MS | Opexa Therapeutics | Autologous myelin reactive T cell (Tovaxin) | SubC | 6-9 M, 30-45 M, or 60-90 M | 16 | 2002 | 1/2 | NCT00587691 |
| 10 | Relapse Remitting MS | Opexa Therapeutics | Autologous myelin reactive T cell (Tovaxin) | SubC | 30-45 M | 150 | 2006 | 2 | NCT00245622 |
| 11 | MS/secondary Progressive MS | Opexa Therapeutics | Autologous T cell (Tcelna/ Imilecleucel-T) | SubC | 30-45M (×5 a yr) ×2 yrs | 183 | 2012 | 2 | NCT01684761 |
| 12 | MS | Northwestern University | Autologous mobilized HSC | IV | Not mentioned | 110 | 2005 | 2 | NCT00273364 |
| 13 | Relapse Remitting MS | National Institute of Allergy and Infectious Diseases (NIAID) | Autologous CD34+ HSC | IV | Not mentioned | 25 | 2006 | 2 | NCT00288626 |
| 14 | Relapsing MS/relapsing remitting MS/secondary progressive MS | National Institute of Allergy and Infectious Diseases (NIAID) | Autologous HSC | IV | 4-7.5M CD34+ cells/kg | 156 | 2019 | 3 | NCT04047628 |
| 15 | MS | Hadassah Medical Organization | Autologous BM MSC | IT and IV | IT (1M/kg) and IV (0.3-1M/kg) | 24 | 2006 | 1/2 | NCT00781872 |
| 16 | MS | Hadassah Medical Organization | Autologous BM MSC | IT and IV | IT (1M/kg) and IV (1M/kg) up to 8 times | 24 | 2013 | 1/2 | NCT04823000 |
| 17 | MS | Talaris Therapeutics | Allogenic HSC | IV | Not mentioned | 3 | 2007 | 1/2 | NCT00497952 |
| 18 | MS | University of Cambridge | Autologous BM MSC | IV | up to 2 M/kg | 10 | 2008 | 1/2 | NCT00395200 |
| 19 | MS/autoimmune disease/cerebellar degeneration/ | Fred Hutchinson Cancer Center | Autologous or syngeneic peripheral blood stem cell | IV | At least 4 M CD34+ cells/kg | 80 | 2008 | 2 | NCT00716066 |
| 20 | Autoimmune disease/nervous system disease | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Autologous adipose MSC | IV | 4 M/kg | 30 | 2010 | 1/2 | NCT01056471 |
| 21 | MS | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Autologous BM MSC | IV | 1-2 M/kg | 26 | 2013 | 1/2 | NCT01745783 |
| 22 | MS | Royan Institute | Autologous BM MSC | IV | Not mentioned | 22 | 2011 | 1/2 | NCT01377870 |
| 23 | Relapse remitting MS/secondary progressive MS/progressive relapsing MS | The Cleveland Clinic | Autologous BM MSC | IV | 1-2 M/kg | 24 | 2011 | 1 | NCT00813969 |
| 24 | MS | University of Jordan | Autologous BM MSC | IT | 13 | 2012 | 2 | NCT01895439 | |
| 25 | MS | University of Jordan | Allogenic WJ MSC | IT and IV | IT(200 M) with 100 M (iv) | 60 | 2017 | 1/2 | NCT03326505 |
| 26 | Progressive MS | North Bristol NHS Trust | Autologous BM cells | IV | Not mentioned | 80 | 2012 | 2 | NCT01815632 |
| 27 | MS | North Bristol NHS Trust | Autologous BM cells | IV | Not mentioned | 4 | 2014 | na | NCT01932593 |
| 28 | Relapse remitting MS | Germans Trias i Pujol Hospital | Autologous BM MSC | IV | 1 M/kg | 9 | 2012 | 1/2 | NCT02035514 |
| 29 | MS | Antonio Uccelli | Autologous BM MSC | IV | 1-2m M/kg | 20 | 2012 | 1/2 | NCT01854957 |
| 30 | MS | Imperial College London | Autologous BM MSC | IV | 1-2 M/kg | 21 | 2012 | 1/2 | NCT01606215 |
| 31 | MS | Karolinska Institutet | Autologous BM MSC | IV | 1-2 M/kg | 7 | 2012 | 1 | NCT03778333 |
| 32 | MS | Translational Biosciences | Allogenic WJ MSC | IV | 140 M (over 7 days, 20 M/day) | 20 | 2014 | 1/2 | NCT02034188 |
| 33 | MS | Sara Varea | Autologous tolerogenic dendritic cells | IV | Not mentioned | 20 | 2015 | 1 | NCT02283671 |
| 34 | MS | Ottawa Hospital Research Institute | Autologous BM MSC | IV | 1-2 M/kg | 31 | 2015 | 2 | NCT02239393 |
| 35 | Relapse remitting MS/secondary progressive MS | Banc de Sang i Teixits | Autologous BM MSC (XCEL-MC-ALPHA) | IV | Not mentioned | 8 | 2015 | 1/2 | NCT02495766 |
| 36 | MS | Dimitrios Karussis | Autologous BM MSC | IT or IV | 1 M/kg | 48 | 2015 | 2 | NCT02166021 |
| 37 | Relapse remitting MS/secondary progressive MS | Centro de Hematología y Medicina Interna | Autologous peripheral blood stem cells | IV | At least 1 M/kg CD34+ cells | 1000 | 2015 | na | NCT02674217 |
| 38 | Relapse-remitting/chronic progressive MS | Fundació Institut Germans Trias i Pujol | Autologous VitD3 tolerogenic monocyte derived dendritic cells (tolDC-VitD3) | intranodal | 5 M, 10 M, 15 M | 16 | 2017 | 1 | NCT02903537 |
| 39 | MS | University Hospital, Antwerp | Autologous tolerogenic dendritic cells (tolDC) | intradermal | 5 M, 10 M, 15 M | 9 | 2017 | 1 | NCT02618902 |
| 40 | Primary and secondary progressive MS | Atara Biotherapeutics | Allogenic T Cell (ATA188) | IV | Not mentioned | 265 | 2017 | 1/2 | NCT03283826 |
| 41 | Chronic progressive MS | Brainstorm-Cell Therapeutics | Autologous BM MSC (NurOwn) | IT | Not mentioned (3 doses) | 20 | 2019 | 2 | NCT03799718 |
| 42 | Relapse-remitting MS | Judith Pich | Autologous peripheral blood differentiated adult tolerogenic dendritic cells | IV | Not mentioned | 45 | 2020 | 2 | NCT04530318 |
| 43 | Relapse remitting MS | FibroBiologics | Tolerogenic fibroblasts | IV | 100 M | 5 | 2020 | 1 | NCT05080270 |
| 44 | MS | Nantes University Hospital | Autologous EBV-specific cytotoxic T-cell lymphocytes | IV | Not mentioned | 7 | 2021 | 1 | NCT02912897 |
| 45 | Relapse remitting MS | Uppsala University | Autologous HSC | IV | Not mentioned | 200 | 2021 | na | NCT05029206 |
| 46 | MS | Hope Biosciences Stem Cell Research Foundation | Adipose MSC (HB-adMSCs) | IV | Not mentioned | 24 | 2021 | 2 | NCT05116540 |
| 47 | Progressive MS | Haukeland University Hospital | Autologous BM MSC | IT | Not mentioned | 18 | 2021 | 1/2 | NCT04749667 |
| 48 | MS | ImStem Biotechnology | ESC MSC (IMS001) | IV | Low or high dose | 30 | 2021 | 1 | NCT04956744 |
Abbreviations: BM, bone marrow; BMSC, bone marrow stem cells; ESC; embryonic stem cells; HSC, hemopoietic stem cells; IT, intrathecal; IV, intravenous; M, million; MS. Multiple sclerosis; MSC, mesenchymal stem cells; na, not applicable NSC, neural stem cells; SubC, subcutaneous; UCB, umbilical cord blood; WJ, Wharton Jelly.